Prostate Cancer Diagnostics Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Prostate Cancer Diagnostics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Prostate Cancer Diagnostics Market:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-diagnostics-global-market-report

According to The Business Research Company’s Prostate Cancer Diagnostics Global Market Report 2024, The prostate cancer diagnostics market size has grown rapidly in recent years. It will grow from $3.86 billion in 2023 to $4.4 billion in 2024 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to increasing aging population, advancements in medical imaging, rising awareness and screening programs, public health initiatives, improved biopsy techniques.

The prostate cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $7.11 billion in 2028 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to integration of artificial intelligence (ai), growth of telemedicine in cancer screening, advancements in genomic profiling, patient-centric approaches, multiparametric mri for diagnosis. Major trends in the forecast period include liquid biopsy technologies, technological advances in biomarker detection, clinical research and development, digital pathology integration, emergence of multiplex biomarker assays.

The increasing prevalence of prostate cancer is expected to propel the growth of the prostate cancer diagnostics market going forward. Prostate cancer is a condition in which cancer arises in the prostate gland, a component of the male and female reproductive systems. Prostate cancer diagnostics helps patients to diagnose the disease early with various tests, including prostate-specific antigen (PSA) testing and sophisticated imaging techniques. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based non-profit organization dedicated to eliminating cancer, approximately 288,300 new cases of prostate cancer and 34,700 deaths attributed to prostate cancer in 2023. Therefore, increasing prevalence of prostate cancer is expected to propel the growth of the prostate cancer diagnostics market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12003&type=smp

The prostate cancer diagnostics market covered in this report is segmented –

1) By Products: Instruments, Reagents And Consumables, Accessories

2) By Test Type: Preliminary Tests, Confirmatory Tests

3) By Prostate Cancer: Squamous Cell Cancer, Small Cell Carcinoma, Transitional Cell Cancer, Prostatic Adenocarcinoma, Ductal Adenocarcinoma, Small Cell Prostate Cancer, Acinar Adenocarcinoma

4) By Peer Groups: Adult, Pediatric, Geriatrics

5) By End User: Hospitals, Independent Diagnostic Laboratories, Cancer Research Institutes, Other End-Users

Technological innovations are a key trend gaining popularity in the prostate cancer diagnostics market. Major companies operating in prostate cancer diagnostics are introducing innovative AI-powered prostate cancer diagnosis tools to sustain their position in the market. For instance, in March 2023, Qritive, a Singapore-based company that develops diagnostic tools, launched QAi Prostate, an advanced AI-powered prostate cancer diagnosis tool for pathologists. These tools include advanced machine learning algorithms that identify the prostatic adenocarcinoma region and analyze whole slide images of prostate core needle biopsies. This tool helps pathologists to perform accurate diagnoses quickly and reduces the time taken for the treatment.

The prostate cancer diagnostics market report table of contents includes: